This article describes the generative, patient-centered, design process used in the development of a prototype VHC intended primarily for use ‘on the go’ by adults with persistent asthma or newly diagnosed COPD.
The prototype AeroChamber2go* spacer device was preferred by patients compared to the A2A† spacer and provides a good option for patients currently using the Metered Dose Inhaler without a spacer while on-the-go.
As a medical device manufacturer, we are committed to minimizing any disruption to the supply of our products to our customers globally, during this unprecedented time with the outbreak of COVID-19.
More consistent dose delivery was achieved with the breath actuated technology rather than breath enhanced.
Delivering medication only when the patient inhales would result in more stable therapy if I:E ratio was to change with disease< progression or if the patient took breaks to talk during treatment.
More consistent dose delivery was achieved with the breath actuated technology rather than breath enhanced. Delivering medication only when the patient inhales would result in more stable therapy if I:E ratio was to change with disease< progression or if the patient took breaks to talk during treatment.
More consistent dose delivery was achieved with the breath actuated technology rather than breath enhanced. Delivering medication only when the patient inhales would result in more stable therapy if I:E ratio was to change with disease< progression or if the patient took breaks to talk during treatment.
